Tokyo Metropolitan Institute for Geriatrics and Gerontology
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hort, Jakub
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
SHINE, NCT03507790 / 2022-002326-27: A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Completed
2
153
Europe, US, RoW
CT1812, Study Drug, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA)
Mild to Moderate Alzheimer's Disease
05/24
05/24
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
Bajacek, Michal
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT06074562: A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Recruiting
2
410
Europe, Japan, US, RoW
LY3556050, Placebo
Eli Lilly and Company
Diabetic Peripheral Neuropathy
07/25
07/25
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29

Download Options